Leuprorelin depot - Daewoong Pharmaceutical

Drug Profile

Leuprorelin depot - Daewoong Pharmaceutical

Alternative Names: DWJ 108J; Leuprolide acetate - Daewoong Pharmaceutical; Luphere; SR Leuprolide

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Precocious puberty; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 12 Jan 2017 Daewoong Pharmaceutical plans a phase I trial for Prostate cancer (SC) (NCT03029533)
  • 15 Mar 2016 Biomarkers information updated
  • 05 Dec 2014 Preclinical trials in Prostate cancer in Russia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top